GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

ublituximab   Click here for help

GtoPdb Ligand ID: 8920

Synonyms: Briumvi® | LFB-R603 | TG-1101 | TGTX-1101 | ublituximab-xiiy
Approved drug Immunopharmacology Ligand
ublituximab is an approved drug (FDA (2022), EMA (2023))
Compound class: Antibody
Comment: Ublituximab is a novel third-generation anti-CD20 monoclonal antibody, CD20 being the B lymphocyte cell surface glycoprotein encoded by the MS4A1 gene. This chimeric antibody has been glycoengineered (namely, having a low fucose content in its Fc region) to optimise FcγRIIIA (CD16a) binding, to enhance antibody-dependent cell-mediated cytotoxicity [1-2]. It is being investigated for its immunomodulatory potential.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Ublituximab shows similar specificity and a similar glycosylation pattern to the anti-CD20 mAb EMAB-6 [1].
Bioactivity Comments
Ublituximab (LFB-R603) mediates 100 times greater antibody-dependent cell-mediated cytotoxicity by natural killer cells from CLL patients and healthy donors than rituximab [2].
Selectivity at other protein targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
CD20 (membrane-spanning 4-domains, subfamily A, member 1) Primary target of this compound Hs Antibody Binding - - - 2
⤷ [2]